Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance...
The estimated rate of 6-month progression-free survival was 29% overall, though it was 50% in one biomarker-defined patient subset.
Onodera’s Prognostic Nutritional Index in soft tissue sarcoma patients as a predictor of wound complications
Background The ability to predict a wound complication after radiation therapy and surgery for soft tissue sarcomas remains difficult....
IntroductionSoft tissue sarcomas (STSs) are rare adult tumors, with 3.4 new cases per 100,000 persons or 12,310 expected new cases in 2016.1...